PMC:7306567 / 15680-15834 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"161","span":{"begin":0,"end":12},"obj":"Chemical"},{"id":"163","span":{"begin":63,"end":78},"obj":"Disease"},{"id":"164","span":{"begin":103,"end":128},"obj":"Disease"}],"attributes":[{"id":"A161","pred":"tao:has_database_id","subj":"161","obj":"MESH:C101425"},{"id":"A163","pred":"tao:has_database_id","subj":"163","obj":"MESH:D015470"},{"id":"A164","pred":"tao:has_database_id","subj":"164","obj":"MESH:D006086"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Posaconazole (POS) prophylaxis reduces the prevalence of IA in neutropenic AML patients and those with graft-versus-host disease following alloHCT [2, 3]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T77","span":{"begin":57,"end":59},"obj":"Disease"},{"id":"T78","span":{"begin":75,"end":78},"obj":"Disease"},{"id":"T79","span":{"begin":103,"end":128},"obj":"Disease"}],"attributes":[{"id":"A77","pred":"mondo_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/MONDO_0000240"},{"id":"A78","pred":"mondo_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/MONDO_0018874"},{"id":"A79","pred":"mondo_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/MONDO_0013730"}],"text":"Posaconazole (POS) prophylaxis reduces the prevalence of IA in neutropenic AML patients and those with graft-versus-host disease following alloHCT [2, 3]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T100","span":{"begin":57,"end":59},"obj":"Chemical"}],"attributes":[{"id":"A100","pred":"chebi_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/CHEBI_74062"}],"text":"Posaconazole (POS) prophylaxis reduces the prevalence of IA in neutropenic AML patients and those with graft-versus-host disease following alloHCT [2, 3]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T26","span":{"begin":75,"end":78},"obj":"Phenotype"}],"attributes":[{"id":"A26","pred":"hp_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/HP_0004808"}],"text":"Posaconazole (POS) prophylaxis reduces the prevalence of IA in neutropenic AML patients and those with graft-versus-host disease following alloHCT [2, 3]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T104","span":{"begin":0,"end":154},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Posaconazole (POS) prophylaxis reduces the prevalence of IA in neutropenic AML patients and those with graft-versus-host disease following alloHCT [2, 3]."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T118","span":{"begin":0,"end":12},"obj":"CHEBI:64355;CHEBI:64355"},{"id":"T66121","span":{"begin":0,"end":12},"obj":"CHEBI:64355;CHEBI:64355"}],"text":"Posaconazole (POS) prophylaxis reduces the prevalence of IA in neutropenic AML patients and those with graft-versus-host disease following alloHCT [2, 3]."}